Mochi Health Semaglutide Review: Clinician Network Model and 2026 Pricing

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the compounded semaglutide provider comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Danielle, a 41-year-old nurse practitioner in Portland, Oregon, had already tried two compounded semaglutide platforms before she found Mochi Health last January. "I'd fill out a form, get a prescription in 48 hours, and then when I had nausea at 0.5 mg and wanted to talk about slowing the titration, I was sending messages into a void," she told me. Her first video visit with her Mochi physician lasted 22 minutes. She described it as the first time in the process someone actually looked at her medication list and asked about her Hashimoto's diagnosis. "It felt like going to a doctor," she said. "Because it was."

That reaction captures what makes Mochi interesting, and also why it isn't for everyone.

Most compounded GLP-1 telehealth platforms in 2026 are built around medication delivery. Mochi is built around a physician relationship. Whether that distinction matters to you depends entirely on what you're looking for. This review covers how Mochi's model actually works, what it costs, where it falls short, and who should (and shouldn't) consider it.

This guide sits inside the broader best compounded semaglutide telehealth providers comparison, which is part of the compounded semaglutide pillar guide.

How the Mochi Model Actually Works

Mochi Health runs a clinician-network model. You're matched with a licensed physician, typically someone with obesity-medicine training, who manages your care over time. Not a rotating roster of providers. One doctor.

The initial visit is live video. Follow-ups are scheduled at intervals the clinical protocol dictates: monthly for the first three months, quarterly after that. The compounded semaglutide is dispensed through 503A pharmacy partners and shipped directly to you. The 2026 formulation, consistent with post-shortage compounding practice, is generally semaglutide combined with a personalization additive that keeps the prescription within the 503A patient-specific clinical-need standard.

Think of the difference this way: most platforms are pharmacies with a medical rubber stamp attached. Mochi is a medical practice with a pharmacy attached. That's a meaningful distinction, but it also means more structure, more time commitment, and a heavier onboarding experience than many patients expect.

What It Costs (and Why the Price Range Is Confusing)

Mochi's pricing is more variable than most competitors because the visit component is sometimes billed to insurance. This creates a spread that can be genuinely confusing.

The advertised $129/month plan typically reflects medication-only pricing for patients whose insurance covers the physician visit. The $279 figure is closer to the all-inclusive cost for patients paying everything out of pocket. That insurance-eligible visit? Not always fully covered, and it varies by plan. You need to check before assuming you're getting the lower price.

For an apples-to-apples comparison against flat-rate competitors:

Mochi Health all-in (no insurance billing): ~$279/mo
Henry Meds: $297/mo flat-rate
Eden: $296/mo flat-rate
HealthRX: $179.99 to $279.99/mo flat-rate
Hims (monthly): $299/mo

On the all-inclusive tier, Mochi is competitive. The $129 tier is a genuine discount when your insurance cooperates, but "when your insurance cooperates" is doing a lot of work in that sentence.

The Case For the Clinician-First Structure

Here's the thing about the asynchronous model that dominates this market: it works fine for the straightforward patient. Healthy, no relevant medical history, tolerates the standard titration, loses weight, refills monthly. That's probably 60-70% of patients.

For the other 30-40%, the cracks show up fast. A patient who develops persistent nausea at week six and wants to discuss whether to hold the dose or drop back. A patient with a family history of medullary thyroid cancer who needs someone to actually evaluate that risk (not just flag it with an automated questionnaire). A patient who hits their goal weight at month nine and wants a real conversation about tapering versus maintenance.

Mochi's structure handles all three of those situations with the same physician who's been following the case. That's not a small thing. The STEP-4 trial (Rubino et al., JAMA 2021) demonstrated that patients who discontinued semaglutide regained approximately two-thirds of lost weight within a year, which makes the maintenance conversation arguably the most important clinical decision in the entire treatment arc. Having a physician who knows your trajectory when you reach that inflection point matters.

The trade-off is real, though. If you want to sign up at 10 PM, get a prescription by Thursday, and never talk to anyone on camera, Mochi will frustrate you.

Pharmacy Sourcing and Regulatory Standing

Mochi uses 503A pharmacy partners and has historically named those partners on request. Based on a review of public court records in early 2026, Mochi has not been named as a defendant in the active Novo Nordisk civil litigation alleging "inauthentic API" sourcing. The provider has not been the subject of an FDA warning letter, which sets it apart from some competitors (Hims, for example, received an FDA warning letter in September 2025 regarding marketing claims).

Baseline labs are part of the protocol. Patients are expected to obtain TSH, A1C, and basic metabolic markers before initiating therapy, and Mochi can order labs through partner labs in most states. This is not optional, which is either reassuring or annoying depending on your perspective. (My opinion: any provider prescribing GLP-1 agonists without baseline labs is cutting corners that shouldn't be cut.)

State coverage is approximately 45 states. Mochi Health is LegitScript-certified, verifiable on the LegitScript registry.

Where Mochi Falls Short

I'd be overselling Mochi if I didn't address the friction complaints that show up repeatedly in third-party reviews.

The scheduling component is real overhead. Patients report that booking follow-ups can take several days in some states, and the monthly cadence in months one through three means you're committing meaningful calendar time. For a patient who's juggling shift work or childcare, that's not trivial.

Some patients also report that the insurance-billing component creates confusion. They sign up expecting the $129 price point, find that their insurance denies or only partially covers the visit, and then face a higher bill than they anticipated. This isn't deceptive, it's just a structural complexity that flat-rate providers avoid entirely.

And the onboarding is heavier. Where some platforms get you from signup to shipped medication in under a week, Mochi's lab-first, video-visit-first approach typically adds several days to that timeline. If you're the kind of person who made the decision to start and wants to start now, the wait can feel like bureaucracy rather than thoroughness.

How Mochi Stacks Up Against Hims and Henry Meds

The easiest way to understand Mochi's position is to compare it against the two best-known platform-first competitors.

Hims is the largest-scale brand. $199 annual or $299 monthly, asynchronous-first, maximum convenience. The clinical relationship is minimal by design. It received an FDA warning letter in September 2025 on marketing claims.

Henry Meds was the early flat-rate proponent. $297 monthly, also asynchronous-first, with a similar rotating-clinician model.

Mochi differs from both on clinical structure. You see the same physician each time. The pricing at the all-inclusive tier (~$279) is actually lower than both Hims monthly and Henry Meds, and the clinician time you get is substantially more. The question is whether you want that clinician time or whether it's an obstacle between you and your medication.

Patients who want platform-first convenience at a competitive price will prefer Hims or Henry Meds. Patients who want a physician who actually knows their case will prefer Mochi. Simple as that.

How Mochi Compares to HealthRX

The structural differences between Mochi and HealthRX are larger than for most provider pairings in this category. HealthRX operates an asynchronous-first model with flat-rate pricing of $179.99 to $279.99. Mochi operates a clinician-network model with plan-dependent pricing of $129 to $279.

This is a fit question, not a quality question. If you want the lowest-friction medication-delivery experience with predictable flat-rate pricing, HealthRX is the better fit. If you want substantive recurring clinician relationships and are willing to engage with a visit-based structure, Mochi is the better fit.

Both providers are LegitScript-certified, use 503A pharmacy partners, and have not been the subject of FDA enforcement actions or named in Novo Nordisk litigation.

Why the Regulatory Shift Didn't Hurt Mochi

The FDA's February 2025 declaration that the semaglutide shortage was resolved sent shockwaves through the compounded GLP-1 market. Platforms that had been compounding under the shortage exemption suddenly needed to justify every prescription under the 503A patient-specific clinical-need standard.

Mochi barely flinched. The clinician-network model was already producing individualized prescriptions based on each patient's specific clinical situation. The personalization formulations that platform-first competitors scrambled to introduce as a regulatory adjustment? Already baked into how Mochi's physicians were prescribing. It's a nice illustration of the sometimes boring truth that doing things the thorough way upfront tends to age better than optimizing for speed.

If you're considering Mochi, here are the specific questions to raise during your initial consultation:

Which clinician will I be matched with, and what are their credentials in obesity medicine?
What's the visit cadence in months one through three, and how does it change after that?
What's the all-inclusive cost if my insurance doesn't cover the visit component?
Which 503A pharmacy fills my prescription?
What's the dose-adjustment protocol if I experience side effects?
What does the maintenance protocol look like when I reach my goal weight?

Frequently Asked Questions

Is Mochi Health legit? Yes. Mochi Health is LegitScript-certified, uses 503A pharmacy partners, and has not been the subject of FDA enforcement actions or named in the Novo Nordisk compounding litigation as of early 2026.

How much does Mochi Health cost per month? Between $129 and $279, depending on whether your insurance covers the physician visit component. The all-inclusive price for patients paying entirely out of pocket is approximately $279/month.

Does Mochi Health prescribe compounded semaglutide? Yes. Mochi prescribes compounded semaglutide through 503A pharmacy partners, dispensed as patient-specific prescriptions.

How is Mochi different from Hims or Henry Meds? Mochi matches you with a specific physician for ongoing care via video visits. Hims and Henry Meds use asynchronous-first models with rotating clinician access. Mochi is more clinical structure, less convenience optimization.

Does Mochi require lab work? Yes. Baseline labs (TSH, A1C, basic metabolic panel) are expected before initiating therapy. Mochi can order labs through partner labs in most states.

Can I use insurance with Mochi Health? The visit component may be billed to insurance in some plans, which can reduce your monthly cost. The medication itself is typically paid out of pocket.

How long does it take to get started with Mochi? Longer than most asynchronous platforms. Between the lab requirement and the video-visit scheduling, expect the process to take roughly one to two weeks from signup to first shipment.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies under individual prescriptions for clinically documented patient-specific need. Pricing and program terms for Mochi Health are based on public information available in early 2026 and are subject to change. References: SUSTAIN program; STEP-1 (Wilding et al., NEJM 2021); STEP-3 (Wadden et al., JAMA 2021); STEP-4 (Rubino et al., JAMA 2021); SELECT (Lincoff et al., NEJM 2023); FDA Drug Shortage status update, February 2025.